Immunocore Holdings plc (NASDAQ:IMCR - Get Free Report) has earned an average rating of "Moderate Buy" from the thirteen research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have issued a buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $63.73.
A number of analysts have weighed in on IMCR shares. HC Wainwright reiterated a "buy" rating and issued a $100.00 price target on shares of Immunocore in a research report on Wednesday, March 12th. Needham & Company LLC reiterated a "buy" rating and issued a $71.00 target price on shares of Immunocore in a research note on Thursday, April 10th. JPMorgan Chase & Co. decreased their price target on Immunocore from $54.00 to $50.00 and set an "overweight" rating on the stock in a research report on Monday, April 14th. Mizuho reduced their price objective on Immunocore from $38.00 to $33.00 and set a "neutral" rating on the stock in a research note on Monday, April 7th. Finally, Morgan Stanley reaffirmed an "equal weight" rating and issued a $35.00 price target on shares of Immunocore in a report on Friday, March 7th.
Get Our Latest Stock Report on Immunocore
Immunocore Price Performance
NASDAQ:IMCR traded up $0.54 during mid-day trading on Tuesday, hitting $28.41. The company's stock had a trading volume of 189,741 shares, compared to its average volume of 440,160. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. The stock has a fifty day moving average of $28.74 and a 200-day moving average of $30.37. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of -29.90 and a beta of 0.75. Immunocore has a fifty-two week low of $23.15 and a fifty-two week high of $62.74.
Insider Buying and Selling
In other news, Director Bros. Advisors Lp Baker bought 807,338 shares of the business's stock in a transaction on Monday, March 17th. The shares were purchased at an average price of $29.72 per share, for a total transaction of $23,994,085.36. Following the purchase, the director now owns 2,144,060 shares of the company's stock, valued at approximately $63,721,463.20. The trade was a 60.40 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.40% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Immunocore
Institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its position in shares of Immunocore by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 35,492 shares of the company's stock valued at $1,047,000 after buying an additional 420 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Immunocore in the 4th quarter valued at $25,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Immunocore by 12.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock valued at $248,000 after acquiring an additional 960 shares during the period. NEOS Investment Management LLC raised its position in shares of Immunocore by 10.9% in the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock valued at $330,000 after buying an additional 1,102 shares in the last quarter. Finally, Assetmark Inc. lifted its holdings in shares of Immunocore by 5.3% during the 4th quarter. Assetmark Inc. now owns 32,171 shares of the company's stock worth $949,000 after acquiring an additional 1,616 shares during the period. Institutional investors and hedge funds own 84.50% of the company's stock.
Immunocore Company Profile
(
Get Free ReportImmunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Further Reading
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
